Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
Completed · Phase 3
Conditions studied: Hypertension
In brief
To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)
Key facts
- Study ID
- NCT00219024
- Run by
- Novartis
- People needed
- 2775
- Starts
- 2004-08-01
- Expected to finish
- 2005-06-01
- Last updated by the study team
- 2017-05-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with essential hypertension
- Patients who are eligible and able to participate in the study
You may not qualify if…
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of hypertensive encephalopathy or cerebrovascular accident
- Other protocol-defined exclusion criteria may apply.
Where it is running
- Novartis Pharmaceuticals — East Hanover, New Jersey, United States
- Study site — Investigative Centers, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.